Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The evaluated claims regarding sequelae of abrupt intrathecal baclofen discontinuation and prevention measures are directly supported by the provided FDA label excerpts from Section 5 (Warnings).
Category Scores
Accurate Statements
Sequelae from abrupt discontinuation/withdrawal of intrathecal baclofen can include high fever.
Section 5 — WARNINGS: “included high fever”
Sequelae include altered mental status.
Section 5 — WARNINGS: “altered mental status”
Sequelae include exaggerated rebound spasticity.
Section 5 — WARNINGS: “exaggerated rebound spasticity”
Sequelae include muscle rigidity.
Section 5 — WARNINGS: “muscle rigidity”
In rare cases, progression can include rhabdomyolysis.
Section 5 — WARNINGS: “in rare cases progressed to rhabdomyolysis”
In rare cases, progression can include multiple organ-system failure.
Section 5 — WARNINGS: “multiple organ-system failure”
In rare cases, progression can include death.
Section 5 — WARNINGS: “and death.”
Prevention requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms.
Section 5 — WARNINGS: “requires careful attention to programming and monitoring of the infusion system, refill scheduling and procedures, and pump alarms.”
Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal.
Section 5 — WARNINGS: “Patients and caregivers should be advised of the importance of keeping scheduled refill visits and should be educated on the early symptoms of baclofen withdrawal.”
Unsupported Statements
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Low
The claim is a warning statement aligned with label content and includes prevention measures; it does not introduce new unsafe or incorrect dosing/safety directions beyond the provided label excerpt.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Suggested Improvement